Factory Supply Afatinib/GILOTRIF CAS 850140-72-6

  • CasNo850140-72-6
  • Molecular FormulaC24H25ClFN5O3
  • Purity99%
  • AppearanceWhite Powder

Product Details

Quick Details

  • CasNo: 850140-72-6
  • Molecular Formula: C24H25ClFN5O3
  • Appearance: White Powder
  • Delivery Time: 3days after we receive the payment
  • Throughput: 1000|Kilogram|Month
  • Purity: 99%

High Purity Afatinib /Afatinib Powder 

Name: Afatinib

CAS number: 439081-18-2

Mol. Mass: 485.937 g/mol

Density: 1.381g/cm3

Boiling Point: 676.917°C at 760 mmHg

Melting Point: 213-215°C

Flash Point: 363.186°C

Afatinib is a drug approved for the treatment non-small cell lung carcinoma(NSCLC), developed by Boehringer Ingelheim.

It acts as a angiokinase inhibitor. As of July 2012, it is undergoing Phase III clinical trials for this indication and breast cancer, as well as Phase II trials for prostate and head and neck cancer, and a Phase I glioma trial. Afatinib is a first-line treatment.

In October 2010 a Phase III trial in NSCLC patients called Lux-Lung 5 began with this drug. Fall 2010 interim results suggested the drug extended progression-free survival threefold compared to placebo, but did not extend overall survival.

In May 2012, the Phase IIb/III trial Lux-Lung 1 came to the same conclusion.

Phase II results for breast cancer that over-expresses the protein human epidermal growth factor receptor 2 (Her2-positive breast cancer) were described as promising by the authors, with 19 of 41 patients achieving benefit from afatinib. Double-blind Phase III trials are under way to confirm or refute this finding. Her2-negative breast cancers showed limited or no response to the drug.


Like lapatinib and neratinib, afatinib is a tyrosine kinase inhibitor (TKI) that also irreversibly inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases. Afatinib is not only active against EGFR mutations targeted by first generation TKIs likeerlotinib or gefitinib, but also against those not sensitive to these standard therapies. Because of its additional activity against Her2, it is being investigated for breast cancer as well as

other EGFR and Her2 driven cancers.

Our Team